Triptorelin Acetate

Summary

Triptorelin Acetate (CHEMBL5315073) is a phase-3 clinical-stage protein; indicated across 3 conditions including infertility disorder and adenomyosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 3 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315073
Name	Triptorelin Acetate
Type	Protein
Max phase	3

Also known as: Ovugel, Triptorelin acetate, TRIPTORELIN ACETATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
infertility disorder	3	MONDO:0005047	EFO:0000545
adenomyosis	0	MONDO:0010888	EFO:1001757

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE4	8
PHASE3	1
PHASE2	1
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01581359	PHASE4	COMPLETED	The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis
NCT02715232	PHASE4	UNKNOWN	Effects of Sex Steroids on the Serotonin System
NCT02825290	PHASE4	UNKNOWN	Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study
NCT03809221	PHASE4	UNKNOWN	The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation
NCT04724343	PHASE4	COMPLETED	Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.
NCT04724486	PHASE4	COMPLETED	Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI
NCT04727671	PHASE4	COMPLETED	Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.
NCT04727684	PHASE4	COMPLETED	Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI
NCT01007851	PHASE3	TERMINATED	Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles
NCT05212857	PHASE2	UNKNOWN	Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
NCT05151016	EARLY_PHASE1	UNKNOWN	Long-term Use of Mifepristone in the Treatment of Adenomyosis
NCT00516490	Not specified	COMPLETED	GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).